Together with pharmacologic LSD1 inhibition, these strategies represent complementary avenues for disarming the CoREST complex in diseases driven by epigenetic dysfunction—including cancer, neurodegeneration, and immune exhaustion. The gene discussed is KDM1A; the disease is cancer.